NONOBESE NAFLD IS ASSOCIATED WITH HIGHER sCD14 CONCENTRATIONS IN ADULTS WITH HIV
Hepatic steatosis is highly prevalent in people living with HIV (PLWH). Additionally, non-obese (BMI
Abstracts
Hepatic steatosis is highly prevalent in people living with HIV (PLWH). Additionally, non-obese (BMI
Affordable direct-acting antivirals are urgently needed to treat hepatitis C virus (HCV) infection in low and middle-income countries. STORM-C-1 aimed to assess the efficacy and safety of ravidasvir plus sofosbuvir in adults chronically infected with HCV, with or without HIV coinfection. STORM-C-1 was a two-stage, open-label, phase 2/3 single-arm clinical trial conducted in 13 public…
Bulk genotyping of blood plasma (BP) is routinely used to identify HIV drug resistance mutations (DRMs) to determine appropriate antiretroviral treatment (ART). Yet, the benefit of genotyping archived proviral DNA to detect preexisting DRMs is not well characterized. Here, we investigated whether deep sequencing of archived proviral HIV DNA in PBMC before ART initiation among…
Genotypic resistance testing (GRT) is not included in management guidelines for those with virologic failure on first-line antiretroviral therapy (ART) in sub-Saharan Africa due to high costs and low availability in the region. The objective of this study was to evaluate the utility of a point-of-care (POC) urine tenofovir (TFV) assay to detect HIV drug…
HIV-1 transmitted drug resistance (TDR) remains a roadblock toward ending the HIV epidemic due to its ability to compromise effectiveness of antiretrovirals for prevention and care. Country- and state-wide TDR data beyond selected surveillance and research efforts are absent, and available estimates are heterogenous. We aggregated [i]all[/i] available HIV-1 [i]pol[/i] partial sequences from treatment-naïve persons…
Non-alcoholic fatty liver disease (NAFLD) is an increasing concern for PLWH. However, information on the impact of NAFLD on the prognosis of PLWH is lacking. Because of these, we investigated the influence of non-alcoholic steatohepatitis (NASH) on the overall mortality in PLWH. PLWH followed in three Spanish centers were included in a prospective cohort at…
People with HIV (PWH) are at high risk for compensated advanced chronic liver disease (cACLD) and hepatic decompensation. While non-invasive tools (NITs) such as liver stiffness measurement (LSM) by transient elastography are used to identify those at risk of hepatic decompensation, these remain not validated and potentially inaccurate in the setting of non-cirrhotic portal hypertension…
Non-alcoholic fatty liver disease (NAFLD) is a common problem in persons with HIV (PWH). NAFLD is associated elevated cardiovascular disease (CVD) risk. We present baseline data on the prevalence and cardiometabolic characteristics of NAFLD among REPRIEVE participants who underwent Computed Tomography (CT). The REPRIEVE Mechanistic substudy is embedded within an international primary CVD prevention RCT…
Metabolic associated fatty liver disease (MAFLD) has been recently proposed as a new concept to describe nonalcoholic fatty liver disease (NAFLD), based on positive diagnostic criteria rather than exclusionary ones. The ongoing debate regarding NAFLD/MAFLD construct has not yet reached HIV arena. Our objective was to characterize MAFLD in comparison to NAFLD and to determine…
Nonalcoholic fatty liver disease (NAFLD) can progress to cirrhosis, hepatocellular carcinoma, and end-stage liver failure. Although NAFLD has become a major cause of liver disease including among persons with HIV (PWH), few studies have examined NAFLD incidence in PWH. We aimed to determine NAFLD incidence among PWH and persons without HIV (PWOH) within the Multicenter…